Our innovation

Targeted small molecule therapeutic
drug for IL-1β-related diseases

The first-in-class oral inhibitor of IL-1β production may be a game-changer in the treatment of various IL-1β-related diseases that currently lack effective treatment options such as autoinflammatory diseases as well as immune-mediated and non-immune mediated inflammatory diseases.

IL-1β serves as a crucial mediator in immune and inflammatory responses. This cytokine plays a pivotal role in defending the body against pathogens such as viruses and bacteria, while also contributing to the regulation of tissue repair processes.

However, despite the important role of IL-1β in the immune response, its prolonged expression over time is associated with a wide variety of diseases.

Our innovation

Alosertib is the
first-in-class oral inhibitor of IL-1β production

In vivo studies demonstrate:

Dose-dependent reduction of IL-1β release in plasma in a LPS mouse model.

Dose-dependent reduction of IL-1β mRNA expression (brain, liver and lung) in a LPS mouse model.

1
1

Alosertib

Inhibitor of IL-1β

Allinky Biopharma Alosertib IL-1β Inhibitor Molecule

In vivo effect of Alosertib on IL-1β release
and IL-1β mRNA expression

Effect of Alosertib on IL-1β in LPS Mouse Model - Allinky Biopharma

Figure 1

Effect of Alosertib on IL-1β (plasma concentration) in a LPS mouse model

Effect of Alosertib on IL-1β in LPS Mouse Model - Allinky Biopharma

Figure 2

IL-1β mRNA expression in brain tissue. LPS induced acute inflammation mouse model

Effect of Alosertib on IL-1β mRNA Expression in Brain Tissue - Allinky Biopharma
Effect of Alosertib on IL-1β mRNA Expression in Liver Tissue - Allinky Biopharma

Figure 3

IL-1β mRNA expression in liver tissue. LPS induced acute inflammation mouse model

Effect of Alosertib on IL-1β mRNA Expression in Liver Tissue - Allinky Biopharma

Figure 4

IL-1β mRNA expression in lung tissue. LPS induced acute inflammation mouse model

Effect of Alosertib on IL-1β mRNA Expression in Lung Tissue - Allinky Biopharma

Discover the indications in which
our inhibitor can stand out as an effective treatment